Schnitzer Steel Industries Inc

Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health.  The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life.  Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging.  Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Schnitzer Steel Industries, Inc. engages in the recycling of ferrous and nonferrous scrap metal and manufacture of finished steel products. The company was founded by Sam Schnitzer in 1906 and is headquartered in Portland, OR.

PORTLAND, Ore.--(BUSINESS WIRE)--Today, TIME named Schnitzer Steel Industries, Inc. dba Radius Recycling's (NASDAQ: RDUS) Chairman and Chief Executive Officer, Tamara Lundgren, to the inaugural TIME100 Climate List, recognizing the 100 most innovative leaders who are working to advocate for and expedite climate action. “Amid the interconnected challenges facing the global business community today, it is critical to align economic progress and climate impact,” said Lundgren. “At Radius, our work.

Radius Recycling Executive Included on TIME100 Climate List of the 100 Most Influential Leaders Driving Business Climate Action

Schnitzer Steel Industries, Inc. (RDUS) Q4 2023 Earnings Call Transcript

PORTLAND, Ore.--(BUSINESS WIRE)--Schnitzer Steel Industries, Inc. dba Radius Recycling (NASDAQ: RDUS) today reported results for the fourth quarter of fiscal 2023 ended August 31, 2023. The Company reported a net loss of $(26) million, or $(23) per ferrous ton, and a loss per share from continuing operations in the fourth quarter of $(0.92), all of which include non-cash goodwill and other asset impairment charges of $45 million, or $1.61 per share. Adjusted earnings per share from continuing o.

Radius Recycling Reports Fourth Quarter and Fiscal 2023 Financial Results

Radius Recycling has experienced management and a strong balance sheet, but there are risks related to commodity prices, the strength of the dollar, and potential impairments. Shares trading below $23 present a multi-year investment opportunity with a margin of safety and asymmetric upside potential of nearly $40. I anticipate RDUS to generate a normalized FCF of 1.50 to 2.3 dollars per share during up-cycle years.

Radius Recycling: Holding After The Rebrand

PORTLAND, Ore.--(BUSINESS WIRE)--Schnitzer Steel Industries, Inc. dba Radius Recycling (NASDAQ: RDUS) announced that the Company will report financial results for its fourth quarter and fiscal 2023 ended August 31, 2023 on Wednesday, October 25, 2023. The Company will host a webcast conference call to discuss the results at 11:30 a.m. Eastern Time on the same day. The webcast of the call and the accompanying slide presentation may be accessed under the Events Calendar on Radius Recycling's webs.

Radius Recycling Announces Fourth Quarter and Fiscal 2023 Earnings Date and Webcast Details

FREIENBACH, Switzerland--(BUSINESS WIRE)--EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical company focused on the development and commercialization of musculoskeletal and rare diseases medications, today announced that it has signed an exclusive licensing and distribution agreement with Radius Health, Inc for Binosto® for the United States. BINOSTO® is indicated for the treatment of osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis. BINOSTO® prov.

EffRx Pharmaceuticals Signs Exclusive Licensing Agreement With Radius Health To Commercialize BINOSTO® In The United States

CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Gurnet Point Capital (“Gurnet Point”) and Patient Square Capital (“Patient Square”) announced today the completion of their acquisition of Radius Health, Inc. (Nasdaq: RDUS) (“Radius”). Radius is a global, commercial-stage biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health and neuro-orphan diseases. Radius' lead product, TYMLOS® (abaloparatide) was launched in the U.S. in 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.

Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from 2L and 3L ER+/HER2- advanced or metastatic breast cancer Submission supported by results from the pivotal Phase 3 EMERALD study of elacestrant showing statistically significant efficacy over current standard-of-care (SOC) medications for both the overall study population and patients whose tumors harbor an ESR1 mutation U.S. FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of February 17, 2023 FLORENCE, Italy and NEW YORK, Aug. 11, 2022 /PRNewswire/ -- The Menarini Group ("Menarini"), a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutics ("Stemline"), a wholly-owned subsidiary of Menarini Group, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for elacestrant, an investigational selective estrogen receptor degrader (SERD), for patients with ER+/HER2- advanced or metastatic breast cancer. The FDA has granted the application Priority Review and assigned a PDUFA date of February 17, 2023.

Menarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer

Dave & Buster's

USA Truck

Evolent Health

GAMCO Investors

Ingles Markets

These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities.

Dave & Busters, USA Truck See Activist Investor Action

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Radius Health, Inc. (NasdaqGM: RDUS) to Gurnet Point Capital and Patient Square Capital. Under the terms of the proposed transaction, shareholders of Radius will receive only $10.00 per share in cash plus a CVR (Contingent Value Right) of $1.00 per share for each share of Radius that they own. KSF is seeking t

RADIUS HEALTH INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Radius Health, Inc. - RDUS

ALPHARETTA, Ga.--(BUSINESS WIRE)--Velan Capital Investment Management LP and Repertoire Partners LP (together with the other participants in their solicitation, “Velan-Repertoire” or “we”), collectively one of the largest stockholders of Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), with beneficial ownership of approximately 7.7% of the outstanding shares and economic exposure to approximately 10.1% of the outstanding shares, today released the following statement: “While we b

Velan-Repertoire to Withdraw Director Nominations Due to Pending Sale of Radius Health

Radius (RDUS) randomizes the first patient in the SCOUT-015 study of pipeline candidate, RAD011, for Prader-Willi Syndrome.

Radius (RDUS) Randomizes Patient in Prader-Willi Syndrome Study

BOSTON, July 07, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today published a detailed investor presentation available at: https://ir.radiuspharm.com/events-and-presentations/.

Radius Health Publishes Investor Presentation Outlining Company's Progress and Board Process Resulting in Agreement to be Acquired at Significant Premium

BOSTON, July 07, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced the first patient has been randomized in the Phase 2/3 pivotal study, SCOUT-015, to evaluate RAD011, a synthetic cannabidiol oral solution, for the treatment of hyperphagia and related neuro-behavioral symptoms in Prader-Willi Syndrome (PWS), a rare neuro-endocrine orphan disease which effects between approximately 20,000 and 30,000 patients in the US.

Radius Announces First Patient Randomized in the RAD011 Pivotal Trial for Prader-Willi Syndrome

Los Angeles, California--(Newsfile Corp. - July 6, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Radius Health, Inc. ("Radius" or "the Company") (NASDAQ: RDUS) for potential breaches of fiduciary duty on the part of its directors and management.If you are a shareholder who has held shares of Radius purchased prior to June 23, 2022, click here to participate.We also encourage...

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Radius Health, Inc. with Losses to Contact the Firm

NEW YORK , July 5, 2022 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) stock prior to June 23, 2022 . You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Radius by Gurnet Point Capital ("Gurnet Point") and Patient Square Capital ("Patient Square").

RDUS ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Radius Health, Inc. by Gurnet Point Capital and Patient Square Capital

NEW YORK , June 27, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Radius Health, Inc. ("Radius Health" or the "Company") (NASDAQ: RDUS), in connection with the proposed acquisition of the Company by Gurnet Point Capital and Patient Square Capital via tender offer.  Under the terms of the merger agreement, the Company's shareholders will receive $ 10.00 per share plus a Contingent Value Right (CVR) of $1.00 per share payable upon TYMLOS® net sales reaching $300 million during any consecutive 12-month period prior to December 31, 2025.

SHAREHOLDER ALERT: Weiss Law Investigates Radius Health, Inc.

Radius (RDUS) will go private following the acquisition by Gurnet Point Capital and Patient Square Capital.

Radius (RDUS) to Go Private With $890M Deal, Shares Gain

Wilmington, Delaware--(Newsfile Corp. - June 24, 2022) - Rigrodsky Law, P.A. is investigating Radius Health, Inc. ("Radius") (NASDAQ: RDUS) regarding possible breaches of fiduciary duties and other violations of law related to Radius' agreement to be acquired by Gurnet Point Capital and Patient Square Capital. Under the terms of the agreement, Radius' shareholders will receive $10.00 in cash and a Contingent Value Right of $1.00 for each share of Radius common stock they own.To learn...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Radius Health, Inc. Merger

ALPHARETTA, Ga.--(BUSINESS WIRE)--Velan Capital Investment Management LP and Repertoire Partners LP (together with the other participants in their solicitation, “Velan-Repertoire” or “we”), collectively one of the largest stockholders of Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), with beneficial ownership of approximately 7.7% of the outstanding shares and economic exposure to approximately 10.1% of the outstanding shares, today issued the following comment in response to t

Velan-Repertoire Comments on Proposed Sale of Radius Health to Gurnet Point Capital and Patient Square Capital

Radius (RDUS) and partner The Menarini Group submit a new drug application to the FDA for elacestrant for treating patients with ER+/HER2- advanced or metastatic breast cancer.

Radius (RDUS), Menarini Submit NDA for Breast Cancer Drug

Why Radius Health Climbed Today

MILWAUKEE , June 23, 2022 /PRNewswire/ -- Ademi LLP is investigating Radius (NASDAQ: RDUS) for possible breaches of fiduciary duty and other violations of law in its transaction with Gurnet Point and Patient Square.  Click here to learn how to join the action: https://www.ademilaw.com/case/radius-health-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Radius Health, Inc. has obtained a Fair Price in its transaction with Gurnet Point and Patient Square

Radius Health Inc (NASDAQ: RDUS) will be acquired by Gurnet Point Capital and Patient Square Capital in a transaction valued at approximately $890 million, including the assumption of debt and assuming full payment of the CVR (Contingent Value Right).  Gurnet Point and Patient.

Bone Health Focused Radius Health Goes Private In $890M Deal

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Radius Health, Inc. (NASDAQ: RDUS) to Gurnet Point Capital and Patient Square Capital is fair to Radius Health shareholders. Under the terms of the merger agreement, Gurnet Point and Patient Square will acquire all of the outstanding shares of Radius for $10.00 per share in cash plus a Contingent Value Right of $1.00 per share payable upon TYMLOS® (abaloparatide) net sales reaching $30

News for Schnitzer Steel Industries Inc Stock (RDUS)